相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Degranulation of human cytotoxic lymphocytes is a major source of proteolytically active soluble CD26/DPP4
Marcus Lettau et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2020)
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
Qihui Wang et al.
CELL (2020)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann et al.
CELL (2020)
DPP4 inhibition: Preventing SARS-CoV-2 infection and/or progression of COVID-19?
Rocky Strollo et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2020)
Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study
Bertrand Cariou et al.
DIABETOLOGIA (2020)
Is DPP4 inhibition a comrade or adversary in COVID-19 infection
Rinkoo Dalan
DIABETES RESEARCH AND CLINICAL PRACTICE (2020)
COVID 19: a clue from innate immunity
Domenico Birra et al.
IMMUNOLOGIC RESEARCH (2020)
COVID-19 in people with diabetes: understanding the reasons for worse outcomes
Matteo Apicella et al.
LANCET DIABETES & ENDOCRINOLOGY (2020)
A Novel Purification Procedure for Active Recombinant Human DPP4 and the Inability of DPP4 to Bind SARS-CoV-2
Cecy R. Xi et al.
MOLECULES (2020)
Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?
Nordin M. J. Hanssen et al.
DIABETES & VASCULAR DISEASE RESEARCH (2019)
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis
Lana C. Pinto et al.
SCIENTIFIC REPORTS (2018)
Lymphocytes are a major source of circulating soluble dipeptidyl peptidase 4
A. Casrouge et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2018)
Association between dipeptidyl peptidase-4 inhibitor drugs and risk of acute pancreatitis A meta-analysis
Shimin Chen et al.
MEDICINE (2017)
The Dipeptidyl Peptidases 4, 8, and 9 in Mouse Monocytes and Macrophages: DPP8/9 Inhibition Attenuates M1 Macrophage Activation in Mice
Yannick Waumans et al.
INFLAMMATION (2016)
Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system
C. Klemann et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2016)
Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo
Sung-Ho Kim et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2016)
Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate
Dong-Sung Lee et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Comparative Binding Analysis of Dipeptidyl Peptidase IV (DPP-4) with Antidiabetic Drugs - An Ab Initio Fragment Molecular Orbital Study
Sundaram Arulmozhiraja et al.
PLOS ONE (2016)
Inflammation in acute and chronic pancreatitis
Aida Habtezion
CURRENT OPINION IN GASTROENTEROLOGY (2015)
Complement Receptor C5aR1/CD88 and Dipeptidyl Peptidase-4/CD26 Define Distinct Hematopoietic Lineages of Dendritic Cells
Hideki Nakano et al.
JOURNAL OF IMMUNOLOGY (2015)
The dipeptidyl peptidase-IV inhibitor inhibits the expression of vascular adhesion molecules and inflammatory cytokines in HUVECs via Akt- and AMPK-dependent mechanisms
Hwan-Jin Hwang et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2015)
Control of adaptive immunity by the innate immune system
Akiko Iwasaki et al.
NATURE IMMUNOLOGY (2015)
Role of the Neutrophil Chemorepellent Soluble Dipeptidyl Peptidase IV in Decreasing Inflammation in a Murine Model of Arthritis
Sarah E. Herlihy et al.
ARTHRITIS & RHEUMATOLOGY (2015)
DPP-4 inhibitors repress foam cell formation by inhibiting scavenger receptors through protein kinase C pathway
Yao Dai et al.
ACTA DIABETOLOGICA (2014)
The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms
Yanmei Zeng et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Endothelial Dysfunction in Chronic Inflammatory Diseases
Curtis M. Steyers et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes
Tesfaye Biftu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Diabetic foot ulcers Part I. Pathophysiology and prevention
Afsaneh Alavi et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Discovery of Imigliptin, a Novel Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
Chutian Shu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis
Veerle Matheeussen et al.
BASIC RESEARCH IN CARDIOLOGY (2013)
Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, Improves Endothelial Dysfunction in Association With Its Anti-Inflammatory Effects in Patients With Coronary Artery Disease and Uncontrolled Diabetes
Junichi Matsubara et al.
CIRCULATION JOURNAL (2013)
A Potential Role for Dendritic Cell/Macrophage-Expressing DPP4 in Obesity-Induced Visceral Inflammation
Jixin Zhong et al.
DIABETES (2013)
Anagliptin, a DPP-4 Inhibitor, Suppresses Proliferation of Vascular Smooth Muscles and Monocyte Inflammatory Reaction and Attenuates Atherosclerosis in Male apo E-Deficient Mice
Nasib Ervinna et al.
ENDOCRINOLOGY (2013)
The Vascular Endothelium and Human Diseases
Peramaiyan Rajendran et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2013)
Dipeptidyl Peptidase IV Is a Human and Murine Neutrophil Chemorepellent
Sarah E. Herlihy et al.
JOURNAL OF IMMUNOLOGY (2013)
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
V. Stalin Raj et al.
NATURE (2013)
Soluble CD26/Dipeptidyl Peptidase IV Enhances the Transcription of IL-6 and TNF-α in THP-1 Cells and Monocytes
Tetsurou Ikeda et al.
PLOS ONE (2013)
Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice
Michishige Terasaki et al.
PLOS ONE (2013)
Neutrophil recruitment and function in health and inflammation
Elzbieta Kolaczkowska et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Macrophages in atherosclerosis: a dynamic balance
Kathryn J. Moore et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
Tomohiro Yoshida et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition
Swenja Kroeller-Schoen et al.
CARDIOVASCULAR RESEARCH (2012)
Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes Role of dipeptidyl peptidase-IV inhibition
Maria Rosaria Rizzo et al.
DIABETES CARE (2012)
Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe -/- mice
F. Vittone et al.
DIABETOLOGIA (2012)
Dipeptidyl Peptidase 4 Inhibition May Facilitate Healing of Chronic Foot Ulcers in Patients with Type 2 Diabetes
Raffaele Marfella et al.
EXPERIMENTAL DIABETES RESEARCH (2012)
Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice
Michishige Terasaki et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2012)
Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor
Aiying Wang et al.
BMC Pharmacology & Toxicology (2012)
The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Attenuates Inflammation and Accelerates Epithelialization in Wounds of Diabetic ob/ob Mice
Christoph Schuermann et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis
Thomas Karagiannis et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor
Noriyasu Kato et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis
Zubair Shah et al.
CIRCULATION (2011)
Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1-Based Therapies
Michael Elashoff et al.
GASTROENTEROLOGY (2011)
Biochemical and Histological Changes in the Small Intestine of Mice With Dextran Sulfate Sodium Colitis
Roger Yazbeck et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2011)
Expression and prognostic assessment of dipeptidyl peptidase IV and related enzymes in B-cell chronic lymphocytic leukemia
Melanie L. Sulda et al.
CANCER BIOLOGY & THERAPY (2010)
Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin
Rajesh Garg et al.
DIABETES CARE (2010)
Dipeptidyl Peptidase Expression During Experimental Colitis in Mice
Roger Yazbeck et al.
INFLAMMATORY BOWEL DISEASES (2010)
Neutrophils: Cinderella of innate immune system
V. Kumar et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2010)
Inhibition of CD26/DPP IV attenuates ischemia/reperfusion injury in orthotopic mouse lung transplants: The pivotal role of vasoactive intestinal peptide
Wolfgang Jungraithmayr et al.
PEPTIDES (2010)
Inflammation and neuropeptides: the connection in diabetic wound healing
Leena Pradhan et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2009)
Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
Roger Yazbeck et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Role of CD26/dipeptidyl peptidase IV in human T cell activation and function
Kei Ohnuma et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: Determinants of potency and in vivo efficacy and safety
Beth A. Connolly et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors
Leo Thomas et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function
Kei Ohnuma et al.
TRENDS IN IMMUNOLOGY (2008)
Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
Debora Williams-Herman et al.
BMC Endocrine Disorders (2008)
Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis
Renee E. Amori et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV
Jun Feng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Discovery of non-covalent dipeptidyl peptidase IV inhibitors which induce a conformational change in the active site
Scott M. Sheehan et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
(3R)-4-1(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
Tesfaye Biftu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
The molecular biology of chronic wounds and delayed healing in diabetes
R. Blakytny et al.
DIABETIC MEDICINE (2006)
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
GA Herman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes - Potential importance of selectivity over dipeptidyl peptidases 8 and 9
GR Lankas et al.
DIABETES (2005)
Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[3-hydroxyadamantan-1-yl) amino]acetyl}-pyrrolidine-2-carbonitrile)
I Brandt et al.
BIOCHEMICAL PHARMACOLOGY (2005)
The multifunctional or moonlighting protein CD26/DPPIV
E Boonacker et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2003)
Neutrophils: Molecules, functions and pathophysiological aspects
V Witko-Sarsat et al.
LABORATORY INVESTIGATION (2000)
分享论文
